Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

A restricted cell population propagates glioblastoma growth after chemotherapy.

Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF.

Nature. 2012 Aug 23;488(7412):522-6. doi: 10.1038/nature11287.

2.

A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.

Jhaveri N, Agasse F, Armstrong D, Peng L, Commins D, Wang W, Rosenstein-Sisson R, Vaikari VP, Santiago SV, Santos T, Chen L, Schönthal AH, Chen TC, Hofman FM.

Cancer Lett. 2016 Feb 28;371(2):240-50. doi: 10.1016/j.canlet.2015.11.040. Epub 2015 Dec 9.

PMID:
26683773
3.

Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.

Auffinger B, Tobias AL, Han Y, Lee G, Guo D, Dey M, Lesniak MS, Ahmed AU.

Cell Death Differ. 2014 Jul;21(7):1119-31. doi: 10.1038/cdd.2014.31. Epub 2014 Mar 7.

4.

Comment re: Temozolomide preferentially depletes cancer stem cells.

Pallini R, Montano N, Larocca LM.

Cancer Res. 2009 Aug 1;69(15):6364; author reply 6365. doi: 10.1158/0008-5472.CAN-09-0036. Epub 2009 Jul 21. No abstract available.

5.

Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.

Beier D, Schulz JB, Beier CP.

Mol Cancer. 2011 Oct 11;10:128. doi: 10.1186/1476-4598-10-128. Review.

6.

MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.

Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C, Nardini D, Sobol RW, Chow LM, Kornblum HI, Waclaw R, Beullens M, Nakano I.

Stem Cells. 2013 Jun;31(6):1051-63. doi: 10.1002/stem.1358.

7.

Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.

Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL.

J Natl Cancer Inst. 2012 Jan 4;104(1):42-55. doi: 10.1093/jnci/djr509. Epub 2011 Dec 15.

8.

Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.

Lai IC, Shih PH, Yao CJ, Yeh CT, Wang-Peng J, Lui TN, Chuang SE, Hu TS, Lai TY, Lai GM.

PLoS One. 2015 Mar 12;10(3):e0114830. doi: 10.1371/journal.pone.0114830. eCollection 2015.

9.

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.

10.

Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.

Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H, Tanaka S.

Cancer Lett. 2013 Apr 30;331(1):68-75. doi: 10.1016/j.canlet.2012.12.005. Epub 2012 Dec 12.

PMID:
23246370
11.

Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.

D'Alimonte I, Nargi E, Zuccarini M, Lanuti P, Di Iorio P, Giuliani P, Ricci-Vitiani L, Pallini R, Caciagli F, Ciccarelli R.

Purinergic Signal. 2015 Sep;11(3):331-46. doi: 10.1007/s11302-015-9454-7. Epub 2015 May 15.

12.

[The sodium pump could constitute a new target to combat glioblastomas].

Lefranc F, Mijatovic T, Kiss R.

Bull Cancer. 2008 Mar;95(3):271-81. doi: 10.1684/bdc.2008.0597. French.

13.

Temozolomide preferentially depletes cancer stem cells in glioblastoma.

Beier D, Röhrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P, Beier CP.

Cancer Res. 2008 Jul 15;68(14):5706-15. doi: 10.1158/0008-5472.CAN-07-6878.

14.

miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.

She X, Yu Z, Cui Y, Lei Q, Wang Z, Xu G, Xiang J, Wu M, Li G.

Oncol Rep. 2014 Sep;32(3):957-64. doi: 10.3892/or.2014.3318. Epub 2014 Jul 10.

PMID:
25017996
15.

Cancer: Resolving the stem-cell debate.

Gilbertson RJ, Graham TA.

Nature. 2012 Aug 23;488(7412):462-3. No abstract available.

PMID:
22919708
16.

Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J, Eliceiri BP, Cance WG.

Mol Cancer Ther. 2013 Feb;12(2):162-72. doi: 10.1158/1535-7163.MCT-12-0701. Epub 2012 Dec 12.

17.

Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.

Le Calvé B, Rynkowski M, Le Mercier M, Bruyère C, Lonez C, Gras T, Haibe-Kains B, Bontempi G, Decaestecker C, Ruysschaert JM, Kiss R, Lefranc F.

Neoplasia. 2010 Sep;12(9):727-39. Erratum in: Neoplasia. 2011 Sep;13(9):5 p following 886.

18.

MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis.

Shi L, Zhang S, Feng K, Wu F, Wan Y, Wang Z, Zhang J, Wang Y, Yan W, Fu Z, You Y.

Int J Oncol. 2012 Jan;40(1):119-29. doi: 10.3892/ijo.2011.1179. Epub 2011 Aug 29.

PMID:
21879257
19.

Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.

Fukushima T, Takeshima H, Kataoka H.

Anticancer Res. 2009 Nov;29(11):4845-54. Review.

20.

Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.

Poelen J, Prick MJ, Jeuken JW, Wesseling P, Bernsen HJ.

Acta Neurol Belg. 2009 Sep;109(3):238-42.

PMID:
19902821

Supplemental Content

Support Center